Allen R. Nissenson - 19 May 2025 Form 4 Insider Report for Elicio Therapeutics, Inc. (ELTX)

Reporting relationship: Director
Issuer ticker: ELTX
Reported as of: 19 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 May 2025, 16:07:35 UTC
Prior SEC filing: 25 Nov 2024
Next SEC filing: 21 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Allen Nissenson

Key filing fact

Allen R. Nissenson filed Form 4 for Elicio Therapeutics, Inc. (ELTX) on 20 May 2025.

Key facts

This page summarizes Allen R. Nissenson's Form 4 filing for Elicio Therapeutics, Inc. (ELTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 20 May 2025, 16:07.

Change

Previous filing in this sequence was filed on 25 Nov 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001441889 Primary reporting owner

Nissenson Allen

Relationship: Director
Address: C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON
Signature: /s/ Allen Nissenson
Signature date: 20 May 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +7,900
Change %
Price: $0.000000
Shares after: 7,900
Date: 19 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,900
Exercise price: $5.84
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option shall vest and become exercisable in full on the earlier of (A) May 19, 2026, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date.